SOSV

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Karma Biotechnologies, Inc. develops therapies for autoimmune diseases. It offers Xavines, a therapeutic to treat autoimmunity, allergies, and food sensitivities. Karma Biotechnologies, Inc. was incorporated in 2019 and is based in Los Angeles, California.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Kite Medical Ltd. is a Galway, Ireland-based company that specializes in developing a non-invasive device for detecting kidney reflux in children with urinary tract infections. Founded in 2016, the company focuses on providing a diagnostic solution that eliminates the need for complicated procedures and hospital visits. Kidney reflux, the most common urological disorder in childhood, affects up to three percent of young children, particularly those aged six months to five years. If left undiagnosed and untreated, the condition can lead to serious complications, including permanent kidney damage and kidney failure. Kite Medical's innovative technology aims to enhance the patient experience and improve clinical outcomes by enabling early detection and monitoring of kidney reflux in a safe and efficient manner.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Convalesce Inc. is a therapeutic company focused on developing stem cell-based therapies for neurodegenerative conditions, including Parkinson's disease. Founded in 2018 and headquartered in San Francisco, California, the company utilizes advanced biomaterials to enhance its treatment approaches. Convalesce aims to address the degeneration of neurons associated with various neurological disorders through innovative therapeutic solutions.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Karma Biotechnologies, Inc. develops therapies for autoimmune diseases. It offers Xavines, a therapeutic to treat autoimmunity, allergies, and food sensitivities. Karma Biotechnologies, Inc. was incorporated in 2019 and is based in Los Angeles, California.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Rize Health is a virtual marketplace for clinical trials that focuses on enhancing the interaction between patients and researchers. Founded in 2019 and based in London, Ontario, the company offers a patient management platform designed to match individuals with suitable clinical trials while facilitating digital participation. The platform includes features such as onboarding, scheduling, and remote data capture, enabling medical professionals to automate the onboarding process for participants and minimize dropout rates. Through its innovative approach, Rize Health aims to streamline the clinical trial experience for both patients and researchers.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Beeline Therapeutics is an early-stage preclinical cell therapy company focused on developing advanced immune cell therapies for immune-mediated diseases, where the body's immune system mistakenly attacks healthy tissue. The company specializes in genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo, aiming to induce tolerance. Specifically, Beeline re-engineers Regulatory T cells (Tregs) to enhance their function by producing optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins. By combining these enhanced Treg capabilities with antigen specificity through targeted receptors, Beeline seeks to improve the localization of therapies, thereby advancing the development of new cell therapies for various immune-mediated conditions.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Bioptamers, Inc. specializes in the development of cellular and gene therapies aimed at treating cancer. Founded in 2018 and headquartered in New Castle, Delaware, with an additional office in São Paulo, Brazil, the company focuses on innovative therapeutic delivery technologies using monoclonal antibodies and antibody-drug conjugates. Bioptamers is creating a platform to optimize aptamer selection, allowing for personalized cancer therapy tailored to individual patient needs. The company aims to transform these specialized molecules into valuable clinical products, which will be licensed to pharmaceutical companies for further development and commercialization.

Guided Clarity, Inc. develops and manufactures bioactive peptides, which target mitochondrial health for the aging population. The company’s products include medical food that isolates individual bioactive proteins with mitochondrial renewing properties. Guided Clarity, Inc. was founded in 2018 and is based in San Francisco, California.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

NeuroQore, Inc. is a Canadian company based in Ottawa, established in 2012, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating resistant cases of depression. The organization is composed of a dedicated team of scientists, engineers, and clinicians who focus on pioneering neuromodulation treatments for various neurobehavioral conditions. NeuroQore collaborates with leading universities and research clinics to explore innovative solutions for major depressive disorder and suicidality, striving to improve the lives of individuals affected by these serious mental health issues. The company's advanced technology is designed for deployment in healthcare facilities globally.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

We are made up of a diverse range of cell types that can mutate or go awry, testing these cells to develop new therapies, to understand diseases or for biopsies is incredibly time-consuming. Cellari enables doctors and non-specialists to take full advantage of recent developments in artificial intelligence. Cellari are providing the most precise “active learning model” for bioimage segmentation combined with an intuitive and easy-to-use user interface for carrying out complex bioimaging tasks. An automated statistical testing service ensures statistical validity of clinical and research related results along with unparalleled review and methodology transparency functionalities.

Clinicai Inc. is a technology company that specializes in health monitoring through innovative bathroom diagnostics. Established in 2016 and located in San Francisco, California, Clinicai develops smart toilet monitoring devices equipped with sensor networks and artificial intelligence. These devices are designed to non-invasively track health by analyzing stool and urine, facilitating early detection of gastrointestinal cancers and other diseases. By creating a connected ecosystem of monitoring platforms and embedded health tracking sensors, Clinicai enables individuals to gather important health data within the home environment, allowing for proactive management of potential health risks.

Convalesce Inc. is a therapeutic company focused on developing stem cell-based therapies for neurodegenerative conditions, including Parkinson's disease. Founded in 2018 and headquartered in San Francisco, California, the company utilizes advanced biomaterials to enhance its treatment approaches. Convalesce aims to address the degeneration of neurons associated with various neurological disorders through innovative therapeutic solutions.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Kite Medical Ltd. is a Galway, Ireland-based company that specializes in developing a non-invasive device for detecting kidney reflux in children with urinary tract infections. Founded in 2016, the company focuses on providing a diagnostic solution that eliminates the need for complicated procedures and hospital visits. Kidney reflux, the most common urological disorder in childhood, affects up to three percent of young children, particularly those aged six months to five years. If left undiagnosed and untreated, the condition can lead to serious complications, including permanent kidney damage and kidney failure. Kite Medical's innovative technology aims to enhance the patient experience and improve clinical outcomes by enabling early detection and monitoring of kidney reflux in a safe and efficient manner.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

Encelo Laboratories Limited develops cell isolation tools that allows researchers, in academia and industry, non-invasive, on-demand, and remote access to an individual’s cells. Its product includes the Cell isolation cup that allows for the selective isolation of live cells from urine and preserves them for shipment. It offers its products and services to pharmaceutical companies, academic researchers, biobanks, and clinicians. The company was founded in 2017 and is based in London, United Kingdom.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

Nivien Therapeutics is a Boston-based company founded in 2016 that focuses on developing innovative treatments for patients suffering from resistant cancers. The company has pioneered the creation of the first small molecule inhibitors of the Hippo signaling pathway, which are designed to enhance both chemotherapy and immunotherapy. Nivien Therapeutics is committed to advancing its unique platform that improves the efficacy of immuno-oncology and chemotherapy combinations, particularly for patients who do not respond to conventional treatments. By collaborating with top research institutes, the company aims to de-risk the transfer of technology assets and build a robust portfolio of biotechnology investments.

NEUROCARRUS INC, a biotechnology company, develops a novel drug delivery technology to disrupt pain signals without addiction-forming medications or disruption of muscular control. The company was incorporated in 2017 and is headquartered in Lincoln, Nebraska.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.